Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Cataract, Retina

Edema Enigma

Macular edema (ME) following cataract surgery isn’t fun for anyone. Although it’s usually self-limiting, it’s particularly bad news for patients’ vision if it persists. That’s why most surgeons like to take a prophylactic approach to ME and use topical steroids and/or topical non-steroidal anti-inflammatory drugs (NSAIDs) before and after surgery. But a recently-published Cochrane Eyes and Vision systematic review might change that perception.

Their review incorporated results from 34 randomized controlled trials that involved over 5,000 patients who received surgery for age-related cataract that reported ME incidence. Of those, 28 studies compared NSAIDs and steroids versus steroids alone, and the remaining six compared NSAIDs directly with steroids. They found:

  • At three months post-op, the risk of poor vision secondary to ME was lower in patients who received NSAIDs and steroids, than steroids alone – but this was classed as “low certainty evidence.”
  • Also classed as “low certainty” was evidence of a reduced risk of NSAIDs and ME at three months post-op.
  • Almost no evidence was found that NSAIDs improve outcomes for patients, with only one study reporting on quality of life – and even then, stated only that there was a “lack of differences between groups.”
  • Inconsistent data regarding central retinal thickness at three months post-surgery (I² = 87%), and little difference in reported BCVA outcomes (inter-group differences were less than 0.1 LogMAR in 31 out of 34 studies).
  • The most notable adverse effects associated with NSAIDs were burning or stinging; there was no evidence of serious adverse effects.
Figure 1. Summary of key results three months post-surgery (1). CI, confidence interval.

So what’s the take home message? Blanche Lim, lead author on the paper explains: “Topical NSAIDs may be beneficial as prophylaxis against ME, however there remains a lack of compelling evidence to suggest any visual benefit in the long run. There is also a paucity of data to determine effectivity in certain at-risk subgroups.” The authors note that future trials are needed to clear up the uncertainty. In the meantime, Lim comments “The inclusion of NSAIDs as a standard regimen perioperatively still remains surgeon-dependent.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. BX Lim et al., “Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery”, Cochrane Database Syst Rev, 11 (2016). [Epub ahead of print]. PMID: 27801522.
About the Author
Ruth Steer

Related Case Study
Uncovering Ocular Comorbidity

| Contributed by Quidel

Related Product Profiles
Sulcus-based enhancement of visual quality

| Contributed by Medicontur Medical Engineering Ltd

Less Steps, More Vision

| Contributed by Medicontur Medical Engineering Ltd

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register